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Abstract
Background: There is increasing recognition of the importance of B lymphocytes in the immunopathogenesis of multiple
sclerosis (MS), encouraging the evaluation of B cell-associated biomarkers in the cerebrospinal fluid (CSF). We aimed to
evaluate the relevance of the B cell chemoattractant CXCL13 as a prognostic marker in patients with clinically isolated
syndrome (CIS) regarding conversion to MS, and to compare it to Barkhof criteria in magnetic resonance imaging (MRI),
oligoclonal bands (OCB) and the polyspecific intrathecal B cell response against measles, rubella and varicella zoster virus
(MRZR).
Methodology/Principal Findings: CXCL13 was determined in a prospective study over 2 years including 46 patients that
remained CIS over follow-up (CIS-CIS), 45 patients that developed MS (CIS-RRMS), and 30 controls using ELISA. CSF CXCL13
was significantly elevated in CIS-RRMS as compared to CIS-CIS and controls (p,0.001). It was significantly elevated in CIS
with OCB (p,0.001), positive MRZR (p=0.04), and gadolinium enhancement in MRI (p=0.02) and showed a significant
correlation with CSF leukocyte count (p,0.001) and QIgG (p,0.001). CXCL13 showed the best positive predictive value
(PPV) of all parameters investigated (70%, 95%-CI: 53–84%), which could be further increased by combination with Barkhof
criteria in MRI (80%).
Conclusions/Significance: Our data indicate the relevance of CXCL13 in CIS to predict conversion to MS. It furthermore
shows CXCL13 to be an important mediator in the inflammatory cascade associated with the polyspecific intrathecal B cell
response that manifests itself in OCB and MRZR.
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Introduction
In most patients who develop multiple sclerosis (MS), the disease
initially manifests itself in a first relapse-like episode known as
clinically isolated syndrome (CIS) [1]. Given the importance of an
early treatment of MS, the challenge in patients with CIS is to
identify those at high risk of future events that would confirm the
diagnosis of MS [2,3]. Consequently, there is an ongoing search
for biomarkers that could help to evaluate the prognosis in CIS
[1,4,5,6]. Increasing recognition of the importance of B lympho-
cytes in the pathogenesis of MS [7] encouraged the evaluation of B
cell-associated biomarkers in the cerebrospinal fluid (CSF) of
patients with MS and CIS. CSF oligoclonal bands (OCB) were
shown to be an independent risk factor in CIS implementing an
almost two-fold increased risk of having a second relapse [8].
Furthermore, we could demonstrate the polyspecific intrathecal B
cell response against the neurotropic viruses measles, rubella and
varicella zoster (‘‘MRZ reaction’’, MRZR) to be of prognostic
relevance in CIS [9]. A key regulator of B cell recruitment in MS is
the chemokine CXCL13 [7]. It belongs to the CXC chemokine
family and is a selective chemoattractant for B lymphocytes and B
helper T cells via its specific receptor CXCR5 [10]. CXCL13 was
found to be present in active MS lesions and to be elevated in CSF
of MS and CIS [11,12,13]. However, previous studies included
only small numbers of patients with CIS (n=22 [11], n=25 [13])
and provided no longitudinal clinical data on the prognostic
relevance of CSF CXCL13 regarding conversion to MS. We
aimed to evaluate the relevance of CXCL13 as a prognostic
marker in CIS and to compare it to established parameters like
Barkhof criteria in magnetic resonance imaging (MRI) [14], OCB
and MRZR.
Methods
Patients
In a prospective study of the Department of Neurology,
University of Ulm (Germany), we collected paired CSF and
serum samples from patients with CIS that remained CIS (CIS-
CIS) over a follow-up of 2 years and from patients with CIS that
developed definite MS of the relapsing-remitting subtype (CIS-
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using Kurtzke’s Expanded Disability Status Scale (EDSS) [15] by
two experienced neurologists in our department (HT and FL),
each unaware of any results on the CSF biomarkers. Lumbar
puncture was performed as part of the routine diagnostic work up
using a atraumatic 22G Sprotte needle and prior to application of
steroids in all patients. The control group consisted of 30 age-
matched patients who presented with infrequent episodic tension-
type headache [16] and showed no evidence of a structural,
haemorrhagic or inflammatory lesion in MRI.
Ethics statement
Written informed consent was obtained from all patients in
accordance with the Declaration of Helsinki, and the study was
approved by the ethics committee of the University of Ulm.
CSF basic analysis and determination of MRZR
Samples were handled in accordance with the BioMS guidelines
[17]. CSF leukocyte count (cells/cu.mm), total protein (g/L),
lactate (mmol/L), the albumin CSF/serum concentration ratio
(Qalb), immunoglobulins G, A and M, and OCB were obtained as
previously described [18,19,20]. Antibody levels against measles,
rubella and zoster were determined using an enzyme-linked
immunosorbent assay (ELISA) according to the instructions as
supplied by the manufacturer (Genzyme Virotech, Ru ¨sselsheim,
Germany) [9]. Quantitative expression of the intrathecal immune
response was based on calculation of the CSF/serum quotients (Q)
of specific antiviral IgG antibodies (IgG[spec]) and total IgG
(IgGtotal): QIgG[spec]=IgGspec[CSF]/IgGspec[serum], and
QIgG[total]=IgGtotal[CSF]/IgGtotal[serum]). The intrathecal
synthesis of antibodies was detected by calculation of the
corresponding antibody indices (AI): AI=QIgG[spec]/QIgG[to-
tal] (Figure 1). In case of an overall intrathecal Ig synthesis above
the reference range (Qlim), Qlim was used instead of QIgG[total]:
AI=QIgG[spec]/Qlim, if QIgG[total].Qlim [21]. The upper
reference range of QIgG[total], Qlim, was calculated according to
Reiber’s formula [21]. AI values $1.5 were considered to be
indicative of intrathecal IgG synthesis against the respective
antigen [21,22,23]. MRZR was considered positive if two or more
AI values were $1.5.
Table 1. Demographic data, CSF, serum and MRI findings in patients with clinically isolated syndrome (CIS) and controls.
CIS all CIS-CIS CIS-RRMS CTRL S*
n (female/male) 91 (53/38) 46 (27/19) 45 (24/21) 30 (19/11) NS
Age [years] 34 (13–77) 37 (17–77) 33 (13–55) 36 (15–71) NS
EDSS 2 (0–6) 2 (0–6) 2.5 (0–5) - NS
CSF cells/mL 5 (0–86) 4 (0–86) 7 (0–29) 1 (0–4) NS
Qalb 5.2 (1.5–14.7) 5.0 (2.4–11.8) 5.4 (1.5–14.7) 4.1 (2.3–8.5) NS
QIgG 3.4 (1.5–14.8) 2.9 (1.5–10.8) 3.9 (1.8–14.8) 2.0 (0.9–4.2) NS
CSF CXCL13 [pg/ml] 3.7 (0–64.4) 1.6 (0–56.1) 9.3 (0–64.4) 0 (0–5.1) p=0.008
Serum CXCL13 [pg/ml] 30.7 (8.6–528.8) 36.1 (12–528.8) 30 (8.6–84.8) 33.3 (13.4–357.5) NS
MRZR 34 26 42 0 p=0.04
OCB 78 63 91 0 p=0.003
Barkhof criteria 15 5 25 0 p=0.002
Barkhof criteria=3 of 4 criteria fulfilled, CIS all=all patients with CIS, CIS-CIS=patients with CIS that remained CIS over follow-up, CIS-RRMS=CIS patients with
conversion to MS over follow-up, CTRL=controls, EDSS=Kurtzke Expanded Disability Status Scale, MRZR=antibody indexes (AI) for measles, rubella, zoster, two or
more AI$1.5, OCB=oligoclonal bands in cerebrospinal fluid only, Qalb=albumin CSF/serum concentration ratio, QIgG=IgG CSF/serum concentration ratio, NS=not
significant, S=statistical significance, * CIS-CIS vs. CIS-RRMS.
Relative frequencies (%) are given for discrete variables, median and range for continuous variables.
doi:10.1371/journal.pone.0011986.t001
Figure 1. Reiber diagram and antibody index. Left side: Reiber diagram visualizing intrathecal IgG synthesis using a double-logarithmic scaling
to present the IgG CSF to serum quotient (QIgG) in relation to the albumin CSF to serum quotient (Qalb), and showing the hyperbolic function Qlim
that indicates the upper reference range of QIgG. In the upper right corner of the diagram, the relative extent of intrathecal IgG synthesis is indicated.
Right side: Formula for antibody index (AI) and Qlim.
doi:10.1371/journal.pone.0011986.g001
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CXCL13 was measured using ELISA (Quantikine; R&D
Systems, Minneapolis, MN) according to the instructions as
supplied by the manufacturer. Samples of 50 ml CSF and 50 ml
serum were used for the ELISA. Details on the application of the
assay for CSF have been published previously by our group [24].
MRI analysis
MRI scans of the brain and spinal cord were performed on a 1.5
tesla whole-body MRI (Symphony Siemens, Erlangen, Germany)
according to a previously fixed protocol including T1-weighted
spin-echo (SE) axial slices with and without application of
gadolinium-DTPA (Gd) as well as T2-weighted SE axial slices.
Hyperintense lesions on T2-weighted MRI.3m m
2 were ana-
lyzed and quantified. Barkhof criteria [14] were considered to be
positive if three of four criteria were fulfilled according to the
standard procedure.
Statistical analysis
Absolute and relative frequencies were given for discrete
variables, median and range for continuous variables. Differences
between CIS-CIS and CIS-RRMS were analyzed by Chi-Square
test and Mann-Whitney U-Test respectively on a univariate basis in
an exploratory sense. To compare raw data of multiple groups, a
non-parametric ANOVA (Kruskal-Wallis analysis of variance on
ranks) was applied, followed in case of significance by Dunn’s
Method. All correlations were studied using Spearman’s rank
correlation coefficient. P-values below 0.05 were considered to be
significant. Sensitivity was calculated as (true-positive/[true-positi-
ve+false-negative]), specificity was calculated as (true-negative/
[true-negative+false-positive]). The positive predictive value (PPV)
was calculated as (true-positive/[true-positive+false-positive]), and
the negative predictive value (NPV) as (true-negative/[true-
negative+false-negative]). For all diagnostic values the exact 95%
confidence intervals were given [25]. To examine the accuracy of
CXCL13 to differentiate CIS-CIS and CIS-RRMS, we used
Receiver Operating Characteristic (ROC) analysis, calculating the
area under the ROC curve (AUROCC). The Youden index was
calculated to determine the cut-off value which maximizes
discriminating accuracy [26].
Results
Of 91 patients with CIS, 45 developed MS over a follow-up of
two years (conversion rate 49.5%). There was no significant
difference regarding age, gender and EDSS distribution between
patients with CIS-RRMS and CIS-CIS at onset of study (Table 1).
MRZR was observed to be positive in 34% of all patients with CIS
(Table 1). It was significantly more frequent in CIS-RRMS as
compared to CIS-CIS (p=0.04), as were positive OCB in CSF
(p=0.003) and Barkhof criteria in MRI (p=0.002).
We observed a significant difference of CSF CXCL13 between
patients with CIS-CIS, CIS-RRMS and controls (p,0.001,
Kruskal-Wallis analysis of variance on ranks, Figure 2), with
post-hoc analysis (Dunn’s Method) showing CSF CXCL13 to be
significantly elevated in CIS-RRMS as compared to CIS-CIS and
controls and to be elevated in CIS-CIS as compared to controls
(p,0.05 each). In contrast, no significant difference of serum
CXCL13 concentrations was observed between the groups
(p=0.08).
CSF CXCL13 was significantly higher in patients with presence
of OCB in CSF as compared to patients who did not show OCB in
CSF (p,0.001). Similarly, it was significantly higher in CIS with
Figure 2. CXCL13 in patients with CIS. A) Boxplot shows CSF concentrations of CXCL13 in patients with CIS-CIS (patients with CIS that remained
CIS over follow-up of two years), CIS-RRMS (CIS patients with conversion to MS over follow-up) and controls (CTRL). P-value refers to comparison of
CIS-CIS, CIS-RRMS and controls. B) Boxplot shows CSF concentrations of CXCL13 in CIS patients with and without oligoclonal bands (OCB) in CSF. P-
value refers to comparison of CIS patients with and without OCB. C) Boxplot shows CSF concentrations of CXCL13 in CIS patients with and without
positive MRZR (‘‘MRZ reaction’’, intrathecal antibody production against measles, rubella and varicella zoster, with two antibody indices $1.5). P-value
refers to comparison of CIS patients with and without MRZR. D) Boxplot shows CSF concentrations of CXCL13 in CIS patients with and without
gadolinium-enhancing lesions in T1-weighted MRI. P-value refers to comparison of CIS patients with and without gadolinium-enhancing lesions. A)–
D) The box represents the 25
th to 75
th quartile, the whiskers represent the range, and the horizontal line in the box represents the median. Black dots
beyond the whiskers indicate outliers, d=number of patients with detectable CXCL13 concentrations in CSF.
doi:10.1371/journal.pone.0011986.g002
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Figure 2).
CSF CXCL13 showed a significant correlation with CSF
leukocyte count (p,0.001, R=0.59, Figure 3) and with CSF
plasma cells count (p=0.03, R=0.31). In addition, we observed a
significant correlation of CSF CXCL13 with the extent of
intrathecal IgG synthesis as measured by the CSF/serum ratio
of IgG (QIgG, p,0.001, R=0.57). In contrast, no correlation of
CSF CXCL13 with blood-CSF barrier function as measured by
Qalb was detectable (p=0.25). We also found no correlation of
CSF CXCL13 with age of CIS patients (p=0.56). Furthermore,
no correlation with duration from onset of symptoms to lumbar
puncture was observed (p=0.13). We found CSF CXCL13 to be
significantly elevated in patients who showed Gd-enhancing
lesions in T1-weighted MRI (p=0.02). ROC analysis followed
by application of the Youden index revealed 7.7 pg/ml as optimal
cut-off value to differentiate between CIS-CIS and CIS-RRMS
(AUROCC 0.64).
Of all markers investigated, OCB showed the highest sensitivity
for conversion of CIS to MS (91%), which could not be improved
by adding any of the other parameters (Table 2). Barkhof criteria
(92%) [14] showed the highest specificity of all single parameters.
CXCL13 showed the best PPV (70%) for predicting conversion
from CIS to MS of all single parameters, and was superior to
Barkhof criteria (67%) and MRZR (64%). PPV could be increased
to 80% by combination of CXCL13 with Barkhof criteria in MRI
(Table 2).
Discussion
Our observation of elevated CSF CXCL13 in CIS is in line with
previous studies that found CXCL13 to be elevated in CSF and
serum across different subtypes of MS as well as in CIS
[11,12,27,28]. CXCL13 was shown to be present in active
inflammatory lesions in MS [12]. It was suggested to derive from
infiltrating macrophages, whereas in some patients with a
secondary progressive course of disease (SPMS) it may also be
produced by follicle-like structures in the leptomeninges [7,12].
Leukocyte recruitment in MS is tightly regulated and involves
sequential interactions between adhesion molecules, chemokines
like CXCL13, and their specific receptors [29]. CXCR5 was
shown to be present on B cells, as well as on a subset of T cells in
blood and lymphatic tissue [30]. Consequently, CXCL13 is likely
to play a key role in the regulation of B cell migration to the
inflamed CNS [12,29]. It furthermore was suggested to influence
the cytokine environment in MS including an auto-regulatory loop
via up-regulation of membrane LTa1b2 on B cells [31].
The correlation of CSF CXCL13 with leukocyte count, plasma
cell count and QIgG confirms previous observations who found
CSF CXCL13 to correlate with inflammatory disease activity in
MS, especially intrathecal Ig production and accumulation of B
and T cells in the CSF [12]. Our observation of elevated CSF
CXCL13 in CIS patients with presence of OCB and positive
MRZR (Figure 2) demonstrates the association of CXCL13 with
the polyspecific intrathecal B cell response in MS, which was
suggested to derive from long-lived plasma cells in an enhanced B
cell-promoting environment [7]. While B cells produce pro-
inflammatory cytokines such as IL-6, IL-12 and lymphotoxin, and
play a role in antigen-presentation [32], they were also reported to
have tissue-protective and anti-inflammatory capacities in MS
including the release of neurotrophic factors such as nerve growth
factor or brain-derived neurotrophic factor [33,34]. Consequently,
the elevation of B cell-associated markers like CXCL13 in the CSF
of patients with CIS could indicate a pro-inflammatory, B cell
promoting environment as well as an upregulation of compensa-
tory protective mechanisms [7]. Molecules involved in B-cell
trafficking and survival like CXCL13 could be promising targets
for immune intervention. They could furthermore contribute to
biomarker patterns that could help to identify patients that
respond to B cell orientated therapies like plasmapheresis.
CXCL13 is no disease-specific marker of MS or CIS:
Particularly high concentrations of CSF CXCL13 can be found
in patients with neuroborreliosis, which is the neuroinflammatory
Figure 3. Relation of CXCL13 to cell count. Dot plot shows CSF
CXCL13 in patients with CIS plotted against CSF leucocyte count.
Straight line represents regression line; correlation was significant
(p,0.001, R=0.59).
doi:10.1371/journal.pone.0011986.g003
Table 2. Sensitivity, specificity, positive (PPV), and negative
(NPV) predictive value in percent (exact 95% confidence
interval in brackets) for CSF and MRI parameters regarding
conversion of clinically isolated syndrome to definite multiple
sclerosis.
Sensitivity Specificity PPV NPV
OCB 91 (97–98) 36 (23–52) 59 (46–70) 81 (58–95)
MRZR 42 (25–61) 74 (55–88) 64 (41–83) 55 (39–70)
CXCL13 62 (46–76) 76 (61–87) 70 (53–84) 69 (54–81)
Barkhof criteria 17 (7–34) 92 (79–98) 67 (30–93) 55 (43–68)
OCB+CXCL13 60 (43–74) 78 (64–89) 71 (54–85) 63 (54–80)
OCB+MRZ 39 (23–58) 74 (55–88) 62 (38–82) 53 (38–69)
OCB+Barkhof 17 (6–33) 95 (82–99) 75 (35–97) 55 (42–67)
CXCL13+MRZ 32 (17–51) 90 (74–98) 77 (46–95) 57 (42–71)
CXCL13+Barkhof 12 (3–27) 98 (87–100) 80 (28–99) 57 (44–68)
MRZ+Barkhof 7 (1–24) 96 (80–100) 67 (9–99) 49 (34–64)
Barkhof=3 of 4 Barkhof criteria fulfilled, MRZR=antibody indexes (AI) for
measles, rubella, zoster, two or more AI$1.5, OCB=oligoclonal bands in
cerebrospinal fluid only.
doi:10.1371/journal.pone.0011986.t002
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Furthermore, CSF CXCL13 was found to be elevated in other
inflammatory CNS diseases including viral meningitis and
encephalitis [12], confirming its role as a suitable marker of B
cell recruitment. Recent evidence also indicates that, apart from
inflammatory CNS diseases, CSF CXCL13 may be of diagnostic
and prognostic relevance in B cell lymphoma of the CNS [36].
Several candidate markers have been investigated as possible
predictors of progression from CIS to MS [4,6,8,14,37,38,39,40].
Besides history and clinical findings, magnetic resonance imaging
(MRI) has become the preferred tool to evaluate the prognosis in
CIS. However, as shown in a meta-analysis evaluating the use of
MRI in MS, MRI studies tend to produce higher estimates of
sensitivity and lower estimates of specificity particularly in short-
term studies [41]. Cerebrospinal fluid (CSF) is a promising source
of biochemical markers in CIS, since the CSF compartment is in
close anatomical contact with the brain interstitial fluid, and
reflects biochemical changes associated with the disease [42,43].
The most relevant statistical parameters to predict conversion
from CIS to MS are the predictive values (PPV, NPV): The
patient’s disease status (CIS-CIS or CIS-RRMS) is unknown and
the clinician needs to determine whether a positive/negative test
result (e.g. the presence or absence of Barkhof criteria in MRI)
indicates that the patient really has/does not have MS. Our data
showed CXCL13 to have the best PPV of all single parameters
investigated and to be superior to Barkhof criteria [14], MRZR
and OCB. In a previous study, we could demonstrate MRZR to
be of prognostic relevance in CIS [9]. However, an important
drawback of MRZR is that its determination currently requires the
application of three different ELISA assays with at least 300 mL
CSF and the same amount of serum necessary. A workable
combined assay (e.g. a multiplex assay) to determine these
antibodies is still not available. Consequently, the determination
of CXCL13 is more practicable, as it requires a smaller amount of
CSF and serum for a single assay. Furthermore, our data
demonstrates CXCL13 to be superior to MRZR to identify CIS
patients at high risk of conversion to MS.
In conclusion, this study underlines the prognostic relevance of
CXCL13 to predict conversion to MS in patients with CIS. We
observed a considerable overlap regarding CSF CXCL13
concentrations between the groups as well as a considerable
overlap in confidence intervals for the predictive values.
Furthermore, due to limitations regarding the number of patients
included (n=91), we observed large confidence intervals especially
for the combined analysis of the different markers. Consequently,
this study should be considered a pilot study that warrants further
validation of CSF CXCL13 as a prognostic marker in a multi-
center approach on a large cohort of patients with CIS. Even
though, our data suggest that CIS patients that show high
CXCL13 concentrations in CSF and fulfill Barkhof criteria in
MRI are at high risk to develop MS and should therefore be
candidates for an early treatment with an immunomodulatory
therapy.
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